ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    dndi | United Kingdom
Previous Study | Return to List | Next Study

Relative Bioavailability Study of Emodepside IR-tablets and Solution

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03383523
Recruitment Status : Completed
First Posted : December 26, 2017
Last Update Posted : June 25, 2018
Sponsor:
Collaborators:
Bayer
Bill and Melinda Gates Foundation
Information provided by (Responsible Party):
Drugs for Neglected Diseases

Brief Summary:
This study evaluates 2 new immediate release (IR)-tablet formulations of emodepside and they will be compared to the oral liquid service formulation (LSF) used in the FIH Single Ascending Dose study (DNDi-EMO-001 study) (CT.gov identifier: NCT02661178)

Condition or disease Intervention/treatment Phase
Filariasis Drug: Emodepside (BAY 44-4400) Phase 1

Detailed Description:

There is an urgent need for a macrofilaricidal drug, killing or sterilizing permanently O. volvulus adult worms, which could be used in individual case management and, after appropriate testing, as an alternative drug to ivermectin in MDA programs. Emodepside is a promising candidate to kill the adult and sexually mature O. volvulus. Emodepside was shown to be macrofilaricidal against a variety of filarial nematodes and is a registered drug for animal health, commercialized by Bayer AG under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril).

A first-in-human (FIH) double-blind, placebo-controlled study of single ascending doses of emodepside in healthy Caucasian men has been conducted and the preliminary results are favourable, and support continuing the Phase I development program. For this reason, new tablet formulations have been developped and the present study will evaluate bioavailability, PK safety and tolerability, and as well food effect of single doses of 2 new immediate release (IR)-tablet formulations of emodepside compared to the oral liquid service formulation (LSF) used in the FIH study.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 77 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

This is a single-centre, open-label, randomized, parallel-group relative bioavailability study in healthy men. The study will be done in 2 parts, as follows:

Part 1 - single oral doses of 5 mg emodepside will be tested:

  • Part 1a - the LSF (reference formulation) and 2 new IR-tablet formulations (test formulations) will be administered in the fasted state.
  • Part 1b - the 2 new IR-tablet formulations will be administered in the fed state (high-fat, high-calorie meal).

Part 2 - single oral doses of 10 mg emodepside will be tested: depending on the results from Part 1, one or both IR-tablet formulations will be administered in the fasted state.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase1,Randomized,Open-Label,Parallel-Group,Relative Bioavailability Study to Investigate PK,Including Food Effect,Safety and Tolerability of Single Doses of New Immediate Release Tablet Formulations of Emodepside (BAY 44-4400),Compared to Oral Solution,in Healthy Male Subjects
Actual Study Start Date : October 30, 2017
Actual Primary Completion Date : March 26, 2018
Actual Study Completion Date : March 26, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Emodepside

Arm Intervention/treatment
Experimental: Part 1a - treatment A
5 mg emodepside LSF, fasted
Drug: Emodepside (BAY 44-4400)
2 tablets compared to the liquid formulation
Other Names:
  • Profender® (in combination with praziquantel) FOR VETERINARY USE
  • Procox® (in combination with toltrazuril) FOR VETERINARY USE

Experimental: Part 1a - treatment B
5 mg emodepside IR-tablet #406, fasted
Drug: Emodepside (BAY 44-4400)
2 tablets compared to the liquid formulation
Other Names:
  • Profender® (in combination with praziquantel) FOR VETERINARY USE
  • Procox® (in combination with toltrazuril) FOR VETERINARY USE

Experimental: Part 1a - treatment C
5 mg emodepside IR-tablet #416, fasted
Drug: Emodepside (BAY 44-4400)
2 tablets compared to the liquid formulation
Other Names:
  • Profender® (in combination with praziquantel) FOR VETERINARY USE
  • Procox® (in combination with toltrazuril) FOR VETERINARY USE

Experimental: Part 1b - treatment D
5 mg emodepside IR-tablet #406, fed
Drug: Emodepside (BAY 44-4400)
2 tablets compared to the liquid formulation
Other Names:
  • Profender® (in combination with praziquantel) FOR VETERINARY USE
  • Procox® (in combination with toltrazuril) FOR VETERINARY USE

Experimental: Part 1b - treatment E
5 mg emodepside IR-tablet #416, fed
Drug: Emodepside (BAY 44-4400)
2 tablets compared to the liquid formulation
Other Names:
  • Profender® (in combination with praziquantel) FOR VETERINARY USE
  • Procox® (in combination with toltrazuril) FOR VETERINARY USE

Experimental: Part 2 - treatment F
2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
Drug: Emodepside (BAY 44-4400)
2 tablets compared to the liquid formulation
Other Names:
  • Profender® (in combination with praziquantel) FOR VETERINARY USE
  • Procox® (in combination with toltrazuril) FOR VETERINARY USE

Experimental: Part 2 - treatment G
2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
Drug: Emodepside (BAY 44-4400)
2 tablets compared to the liquid formulation
Other Names:
  • Profender® (in combination with praziquantel) FOR VETERINARY USE
  • Procox® (in combination with toltrazuril) FOR VETERINARY USE




Primary Outcome Measures :
  1. PK (AUC0-7d) of two new tablet formulations of emodepside in comparison to the liquid formulation (LSF) oral solution. [ Time Frame: 7 days ]
  2. PK (Cmax) of two new tablet formulations of emodepside in comparison to the liquid formulation (LSF) oral solution. [ Time Frame: 7 days ]

Secondary Outcome Measures :
  1. safety and tolerability as measured by number of participants with treatment-related adverse events [ Time Frame: 7 days ]
  2. safety and tolerability as measured by Number of participants with physical examination findings [ Time Frame: 7 days ]
  3. safety and tolerability as measured by Number of participants with neurological examination findings [ Time Frame: 7 days ]
  4. safety and tolerability as measured by Number of participants with vital signs findings [ Time Frame: 7 days ]
  5. safety and tolerability as measured by Number of participants with 12-lead ECG findings [ Time Frame: 7 days ]
  6. safety and tolerability as measured by Number of participants with clinical laboratory tests findings [ Time Frame: 7 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   male only
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male, Caucasian volunteers, deemed healthy based on a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine.
  2. 18 to 45 years of age
  3. Normal body weight (Body Mass Index (BMI); Quetelet index) in the range 18.0 to 30.1 kg/m2 at screening
  4. Mean blood pressure and heart rate (from the triplicate readings) in the supine position at the screening assessment outside one (or more) of the ranges: 90-140 mm Hg systolic BP 60-90 mm Hg diastolic BP 45-100 beats/min HR
  5. Sufficient intelligence to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire trial
  6. Willingness to give written consent to participate, after reading the information and consent form, and after having the opportunity to discuss the trial with the Investigator or his delegate
  7. Willingness to give written consent to have data entered into The Overvolunteering Prevention System (TOPS)
  8. Willingness to follow contraception requirements of the study, from the first dose of the IMP until 90 days after dosing and inform HMR as soon as possible if their partner becomes pregnant in the 90 days after dosing

    Exclusion Criteria:

  9. Administration of a licensed or unlicensed medicinal product as part of another clinical trial in the 3 months before the first dose of study medication, or within 5 half-lives of administration of a medicinal product given in the previous study (whichever is longer), or otherwise in the follow-up period for any clinical trial
  10. Clinically relevant abnormal medical history, concurrent medical condition, acute or chronic illness, or history of chronic illness (such as diabetes mellitus or other abnormalities of glucose homeostasis) sufficient to invalidate the subject's participation in the trial or make it unnecessarily hazardous
  11. Past surgery (e.g. stomach bypass) or medical condition that might affect absorption of the study drug when taken orally
  12. Presence of abnormal physical findings, ECG, or laboratory values at the screening assessment that could interfere with the objectives of the trial or the safety of the subject
  13. Loss of more than 400 mL of blood within the 3 months before admission
  14. Clinically relevant history of vital organ disease, or other organ or central nervous system disease (e.g. diabetes mellitus, liver disease, seizures, etc.)
  15. Current or previous medical or psychiatric disorder that, in the opinion of the Investigator or the Sponsor, would increase the risk and ability to participate in and/or complete the study
  16. Positive test for hepatitis B, hepatitis C or HIV
  17. Febrile illness (e.g. fever) within 1 week before the first dose of study medication
  18. History of a severe allergy, non-allergic drug reaction, severe adverse reaction to any drug, or multiple drug allergies
  19. Hypersensitivity to any ingredient of the study medication, including the active ingredient (emodepside)
  20. Presence or history of drug or alcohol abuse in the last year, or intake of more than 21 units (1 unit = 1/2 pint of beer, 1 small glass of wine or 1 measure of spirits) of alcohol weekly
  21. Regular daily consumption of more than one litre of beverages containing xanthine
  22. Daily consumption of more than 10 cigarettes or more than 6 grams (1/4 ounce) of tobacco
  23. Use of a prescription medicine during the 28 days before the dose of study medication, or use of an over-the-counter medicine (with exception of acetaminophen (paracetamol)), during the 7 days before the dose of study medication
  24. Use, within 14 days before the dose of study medication, of dietary supplements or herbal remedies (such as St John's Wort) that are known to be inducers or inhibitors of CYP3A4, or other co-medications known to be relevant substrates of CYP3A4 (see list in the Study Procedures Manual)
  25. Use, within 14 days before the dose of study medication, of dietary supplements or herbal remedies that are known to be strong inhibitors of P-gp, or other co-medications known to be relevant substrates of P-gp (see list in the Study Procedures Manual)
  26. Relevant pathological abnormalities in the ECG at screening, such as:

    second or third-degree atrioventricular (AV) block prolongation of the QRS complex > 120 msec, QTc-interval (QTcB or QTcF) > 450 msec. The mean of the triplicate ECG readings will be used to assess eligibility.

  27. Evidence of drug abuse (via urine testing) at the screening assessment or admission to the ward
  28. Use of excluded therapies that may impact on the interpretation of study results in the opinion of the Investigator or Sponsor
  29. Objection by General Practitioner (GP) to subject entering trial
  30. History of residing for 6 or more continuous months during the last 3 years in regions with endemic parasitic infections, as determined by the Investigator
  31. Possibility that subject will not cooperate with the requirements of the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03383523


Locations
United Kingdom
Hammersmith Medicines Research (HMR) Limited
London, United Kingdom, NW10 7EW
Sponsors and Collaborators
Drugs for Neglected Diseases
Bayer
Bill and Melinda Gates Foundation
Investigators
Principal Investigator: Jeremy Dennison Hammersmith Medicines Research (HMR)

Responsible Party: Drugs for Neglected Diseases
ClinicalTrials.gov Identifier: NCT03383523     History of Changes
Other Study ID Numbers: DNDI-EMO-03
2017-003091-31 ( EudraCT Number )
First Posted: December 26, 2017    Key Record Dates
Last Update Posted: June 25, 2018
Last Verified: November 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Filariasis
Spirurida Infections
Secernentea Infections
Nematode Infections
Helminthiasis
Parasitic Diseases
Praziquantel
Anthelmintics
Antiparasitic Agents
Anti-Infective Agents